Skip to main navigation

Investor Relations

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Press Releases

Year

Nov 16, 2023

Kiromic BioPharma Announces Uplisting to OTCQB Market

Nov 09, 2023

Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

Oct 23, 2023

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

Sep 13, 2023

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

Jul 24, 2023

Kiromic BioPharma Welcomes Two New Directors to its Board

May 01, 2023

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

Apr 03, 2023

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

Mar 10, 2023

Kiromic BioPharma Announces Reverse Stock Split

Feb 28, 2023

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

Feb 23, 2023

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Investor Tools

Print

RSS Feeds

Email Alerts

Investor Contact

Copyright © 2023 Kiromic BioPharma, Inc. All rights reserved.